Download Files:
SKLB325
$350 – $1,950
Products Details
Product Description
– SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis[1]. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) [2].
Web ID
– HY-139782
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C12H12N4O2
References
– [1]Heng Zheng, et al. Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal Transduct Target Ther.2019 Jul 26;4:24.|[2]Chuanjie Zhang, et al. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma. Clin Transl Med. 2021 Feb;11(2):e328.
Molecular Weight
– 244.25
Compound Purity
– 99.79
SMILES
– OC1=NC(N/N=C/C2=CC=CC=C2O)=NC(C)=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 20.83 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Apoptosis;Histone Demethylase
Pathway
– Apoptosis;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
